Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML

The purpose of this study is to assess the safety, pharmacokinetic profile of Lisaftoclax (APG-2575) single agent and in combination with HHT/AZA in patients with relapsed/refractory AML and related myeloid malignancies.

Trial Details

NCT ID
NCT04501120
Phase
PHASE1 / PHASE2
Sponsor
Ascentage Pharma Group Inc.
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • Lisaftoclax (APG-2575)
  • Reduced-dose HHT
  • standard-dose HHT
  • Azacitidine
  • olverembatinib
Locations (sample)
  • Beijing, Beijing Municipality, China|39.9075,116.39723
  • Chongqing, Chongqing Municipality, China|29.56026,106.55771
  • Guangzhou, Guandong, China|23.11667,113.25
  • Guangzhou, Guangdong, China|23.11667,113.25
  • Zhengzhou, Henan, China|34.75778,113.64861

Key Eligibility Criteria

  • Subjects who meet each of the following inclusion criteria are eligible to participate in this study:
  • In accordance with the World Health Organization (WHO) 2016 diagnostic criteria for relapsed or refractory acute myeloid leukemia (AML), Mixed phen…
  • Eastern Cooperative Oncology Group (ECOG) Performance Status (PS): 0 -2 (0 to 3 for participants \>= 60 to 74 years of age who are evaluated as ine…
  • Subjects can accept oral administration of Lisaftoclax (APG-2575).

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →